Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

Jianming Ying, Zifen Gao, Hongyu Li, Gopesh Srivastava, Paul G. Murray, Hwee Koon Goh, Chai Yen Lim, Yajun Wang, Teresa Marafioti, David Y. Mason, Richard F. Ambinder, Anthony T.C. Chan, Qian Tao

Research output: Contribution to journalArticle

Abstract

Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2′- deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

Original languageEnglish (US)
Pages (from-to)829-832
Number of pages4
JournalBritish journal of haematology
Volume136
Issue number6
DOIs
StatePublished - Mar 1 2007

    Fingerprint

Keywords

  • Biomarker
  • Lymphoma
  • Methylation
  • PCDH10
  • Tumour suppressor gene

ASJC Scopus subject areas

  • Hematology

Cite this

Ying, J., Gao, Z., Li, H., Srivastava, G., Murray, P. G., Goh, H. K., Lim, C. Y., Wang, Y., Marafioti, T., Mason, D. Y., Ambinder, R. F., Chan, A. T. C., & Tao, Q. (2007). Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. British journal of haematology, 136(6), 829-832. https://doi.org/10.1111/j.1365-2141.2007.06512.x